GLP-1 RAs may improve acne and HS through sebaceous gland modulation, metabolic-immune pathway effects, and androgen reduction, with emerging evidence also supporting psoriasis improvement.
Skin-metabolism connectionGLP-1 drugs may improve acne, HS, and psoriasis by treating the metabolic dysfunction that drives inflammatory skin disease
What the researchers found
GLP-1 RAs may improve acne (sebaceous/androgen modulation), HS (anti-inflammatory/weight reduction), and psoriasis (immunomodulation) through the metabolic-immune axis connecting obesity/diabetes to inflammatory skin disease.
Why it matters
These three skin conditions affect tens of millions and are worsened by obesity. GLP-1 drugs that address both the metabolic cause and inflammatory skin effects could provide dual benefit.
How the study worked
Review of emerging evidence on GLP-1 RA effects on acne, hidradenitis suppurativa, and psoriasis, covering metabolic, hormonal, and immune mechanisms.
What this study cannot tell us
Mostly case reports and small studies. No dedicated skin condition RCTs for GLP-1 drugs. Mechanisms largely theoretical.
How to read the evidence
Review of emerging case-level evidence. Promising but insufficient for clinical recommendations.
When this study was published
Published in 2025.
The bigger picture
The skin-metabolism connection is becoming clearer: treating metabolic disease with GLP-1 drugs may resolve inflammatory skin conditions through shared pathways.
Questions still open
- Should dermatologists consider GLP-1 drugs for refractory skin conditions?
- Would skin outcomes be formal endpoints in future GLP-1 trials?
- Does dose-response exist for skin benefits?
Common questions
Can GLP-1 drugs help skin problems?
Why would a diabetes drug help skin?
Read the original research
The Impact of Glucagon-Like Peptide-1 (GLP-1) Agonists on Acne, Hidradenitis, and Sebaceous Activity.
Cureus, 18(1), e101212
Citation
Jabin, Azra; Khan, Shahab; Khan, Hammad; Durrani, Zain Ullah; Hamza, Khizer; Gul, Faiza; Atta Ullah, Sana; Dayam, Fahad; Yaseen, Muhammad; Shah, Saleem. (2026). The Impact of Glucagon-Like Peptide-1 (GLP-1) Agonists on Acne, Hidradenitis, and Sebaceous Activity.. Cureus, 18(1), e101212. https://doi.org/10.7759/cureus.101212